KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Change in Receivables (2020 - 2021)

Recursion Pharmaceuticals (RXRX) has disclosed Change in Receivables for 2 consecutive years, with -$16000.0 as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Change in Receivables fell 100.05% year-over-year to -$16000.0, compared with a TTM value of -$114000.0 through Dec 2021, down 2380.0%, and an annual FY2021 reading of -$114000.0, down 2380.0% over the prior year.
  • Change in Receivables was -$16000.0 for Q3 2021 at Recursion Pharmaceuticals, down from -$13000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $30.2 million in Q3 2020 and bottomed at -$30.0 million in Q4 2020.